Current Report Filing (8-k)
January 23 2019 - 4:33PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): January 16, 2019
GALECTIN THERAPEUTICS INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Nevada
|
|
001-31791
|
|
04-3562325
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
4960 PEACHTREE INDUSTRIAL BOULEVARD, STE 240
NORCROSS, GA 30071
(Address of principal executive office) (zip code)
Registrants telephone number, including area code: (678)
620-3186
N/A
(Former name or
former address, if changed since last report)
Check the appropriate box below
if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
On January 16, 2019, the Board of Directors of Galectin Therapeutics, Inc. (the
Company) approved retention bonuses payable to certain employees of the Company, including Harold H. Shlevin, the Companys Chief Executive Officer, and Jack W. Callicutt, the Companys Chief Financial Officer, equal to 25% of
such employees then annual salary (the Retention Bonuses) if such employees remain employed by the Company on each of June 30, 2019, December 31, 2019, June 30, 2020, and December 31, 2020. The applicable
payments will be made within fifteen (15) days after the applicable measurement date.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, Galectin Therapeutics Inc. has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
Galectin Therapeutics Inc.
|
|
|
|
|
Date: January 23, 2019
|
|
|
|
By:
|
|
/s/ Jack W. Callicutt
|
|
|
|
|
|
|
Jack W. Callicutt
|
|
|
|
|
|
|
Chief Financial Officer
|
Galectin Therapeutics (NASDAQ:GALT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Galectin Therapeutics (NASDAQ:GALT)
Historical Stock Chart
From Jul 2023 to Jul 2024